TBPHTheravance Biopharma, Inc.

$716M

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$14M-28.2% YoY

Gross Profit

-$53M-374.1% margin

Operating Income

-$84M-588.4% margin

Net Income

-$80M-558.9% margin

EPS (Diluted)

$-1.24

QoQ Revenue Growth

-23.9%

Cash Flow

Operating Cash Flow

-$70M

Free Cash Flow

-$72M

Stock-Based Comp.

$16M

Balance Sheet

Total Assets

$375M

Total Liabilities

$748M

Stockholders' Equity

-$373M

Cash & Equivalents

$114M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$14M	$20M	-28.2%
Gross Profit	-$53M	$20M	-368.6%
Operating Income	-$84M	-$72M	-15.8%
Net Income	-$80M	-$83M	+4.1%

Revenue Segments

Nebulized T D4208

$160M73%

Future Potential Combination Products

$45M21%

Co Promote Agreement

$10M5%

Collaborative Arrangement Revenue

$4M2%

TBPH Q1 2021 Earnings — Theravance Biopharma, Inc. Revenue & Financial Results | Market Cap Arena